Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 321-326

  Kouanfack, Charles ^a   Aghokeng, Avelin F ^b,c   Mondain, Anne Marie ^d   Bourgeois, Anke ^b,e   Kenfack, Alain ^a   Mpoudi Ngolé, Eitel ^c   Ducos, Jacques ^d   Delaporte, Eric ^b,e   Laurent, Christian ^b  

^a YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Institute of Medical Research and Medicinal Plant Studies Yaounde   (Cameroon)

^d INSERM   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CAMEROON; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENETIC SCREENING; GENOTYPE; HEALTH SURVEY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MUTATION RATE; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; BASE SEQUENCE; CAMEROON; COINFECTION; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; SEQUENCE ANALYSIS, DNA;

EID: 84860333499     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1911     Document Type: Article

References (28)

1. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9:25-39. (Pubitemid 46730281)
2. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. (Accessed 1 December 2010). Available from: http://www.unaids.org/documents/ 20101123-GlobalReport-em.pdf
3. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402-409. (Pubitemid 46765200)
4. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010; 14:e1024-e1031.
5. World Health Organization. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. (Accessed 13 October 2010). Available from http://whqlibdoc.who.int/publications/2010/ 9789241500395-eng.pdf
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. (Accessed 12 October 2010). Available from http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf
7. Ford N, Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010; 5:38-47.
8. De Beaudrap P, Diallo MB, Landman R, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses 2010; 26:1221-1227.
9. Matthews G V, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870. (Pubitemid 43731568)
10. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48:353-367.
11. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for secondline treatment. Clin Infect Dis 2009; 48:1318-1322.
12. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based realtime reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007; 45:380-388. (Pubitemid 47057665)
13. Lauritsen JM & Bruus M. EpiData (version 3). A comprehensive tool for validated entry and documentation of data. Odense, Denmark: The EpiData Association 2003-2004.
14. Laurent C, Bourgeois A, Mpoudi-Ngole E, et al. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med 2010; 11:85-89.
15. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 Suppl:S6-S9. (Pubitemid 43053865)
16. Geretti AM, Patel M, Sarfo FS, et al. Detection of highly prevalent hepatitis B virus coinfection among HIVseropositive persons in Ghana. J Clin Microbiol 2010; 48:3223-3230.
17. Mendes-Correa MC, Pinho JR, Locarnini S, et al. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. J Med Virol 2010; 82:1481-1488.
18. Wongprasit P, Manosuthi W, Kiertiburanakul S, Sungkanuparph S. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Patient Care STDS 2010; 24:205-209.
19. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306. (Pubitemid 29510871)
20. Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:557-561. (Pubitemid 46594899)
21. Damerow H, Yuen L, Wiegand J, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010; 82:1850-1858.
22. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
23. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614-2621. (Pubitemid 46961006)
24. Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudineexperienced and lamivudine-naive patients. AIDS 2008; 22:947-955. (Pubitemid 351652245)
25. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399-1410.
26. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev 2007; 20:426-439. (Pubitemid 47175012)
27. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35:14-20. (Pubitemid 43020947)
28. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007; 79:1650-1654. (Pubitemid 47479881)